DGAP-News
Biotest AG: Biotest opens new plasma collection centre in Vermillion, South Dakota, USA
DGAP-News: Biotest AG / Key word(s): Miscellaneous
Biotest AG: Biotest opens new plasma collection centre in Vermillion, South
Dakota, USA
28.09.2016 / 09:16
The issuer is solely responsible for the content of this announcement.
Biotest AG: Biotest opens new plasma collection centre in Vermillion, South
Dakota, USA
28.09.2016 / 09:16
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
/
PRESS RELEASE
Biotest opens new plasma collection centre in Vermillion, South Dakota, USA
- 13 plasma collection centres in Europe
- 21 in the US to ensure long-term plasma supply
Dreieich, 28 September 2016. Biotest Pharmaceuticals Corporation (BPC),
Boca Raton, USA, a 100% subsidiary of Biotest AG, Germany, a leading
manufacturer of plasma proteins and biological products, is pleased to
announce the addition of its newest plasma collection centre located at
Vermillion, South Dakota, USA. The state-of-the-art facility officially
opened its doors for business on September 26, 2016 and brings the total
number of BPC's plasma collection centres to 21.
"The opening of our 21st centre further reinforces our continued commitment
to the expansion of our existing network of plasma collection centres. We
are fully dedicated to better serve the thousands of patients worldwide who
rely on plasma- based therapies", said Ileana Carlisle, BPC's Chief
Executive Officer.
BPC has invested approximately EUR1.6 million in the construction of this
facility. The company expects to add over 40 jobs to the Vermillion local
economy and currently has employment opportunities available for medical
personnel.
About human blood plasma
Human blood plasma is a raw material used to produce plasma derived
products, which are used to treat various illnesses of the immune system,
the blood system, as well as in emergency medicine. Biotest is one of the
world's six largest manufacturers of plasma protein products.
About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value
added chain that extends from pre-clinical and clinical development to
worldwide sales, Biotest has specialised primarily in the areas of clinical
immunology, haematology and intensive medicine. Biotest develops and
markets immunoglobulins, coagulation factors and albumins based on human
blood plasma. These are used for diseases of the immune and haematopoietic
systems. In addition Biotest develops monoclonal antibodies in the
indications of cancer of plasma cells and systemic lupus erythematosus
which are produced by recombinant technologies. Biotest has more than 2,400
employees worldwide. The preference shares of Biotest AG are listed in the
SDAX on the Frankfurt stock exchange.
IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406
email: investor_relations@biotest.de
PR contact
Dirk Neumüller
phone: +49-6103-801-269
email: pr@biotest.de
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany www.biotest.de
Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover,
Munich, Stuttgart
Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.
---------------------------------------------------------------------------
28.09.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations@biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
505879 28.09.2016
/
PRESS RELEASE
Biotest opens new plasma collection centre in Vermillion, South Dakota, USA
- 13 plasma collection centres in Europe
- 21 in the US to ensure long-term plasma supply
Dreieich, 28 September 2016. Biotest Pharmaceuticals Corporation (BPC),
Boca Raton, USA, a 100% subsidiary of Biotest AG, Germany, a leading
manufacturer of plasma proteins and biological products, is pleased to
announce the addition of its newest plasma collection centre located at
Vermillion, South Dakota, USA. The state-of-the-art facility officially
opened its doors for business on September 26, 2016 and brings the total
number of BPC's plasma collection centres to 21.
"The opening of our 21st centre further reinforces our continued commitment
to the expansion of our existing network of plasma collection centres. We
are fully dedicated to better serve the thousands of patients worldwide who
rely on plasma- based therapies", said Ileana Carlisle, BPC's Chief
Executive Officer.
BPC has invested approximately EUR1.6 million in the construction of this
facility. The company expects to add over 40 jobs to the Vermillion local
economy and currently has employment opportunities available for medical
personnel.
About human blood plasma
Human blood plasma is a raw material used to produce plasma derived
products, which are used to treat various illnesses of the immune system,
the blood system, as well as in emergency medicine. Biotest is one of the
world's six largest manufacturers of plasma protein products.
About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value
added chain that extends from pre-clinical and clinical development to
worldwide sales, Biotest has specialised primarily in the areas of clinical
immunology, haematology and intensive medicine. Biotest develops and
markets immunoglobulins, coagulation factors and albumins based on human
blood plasma. These are used for diseases of the immune and haematopoietic
systems. In addition Biotest develops monoclonal antibodies in the
indications of cancer of plasma cells and systemic lupus erythematosus
which are produced by recombinant technologies. Biotest has more than 2,400
employees worldwide. The preference shares of Biotest AG are listed in the
SDAX on the Frankfurt stock exchange.
IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406
email: investor_relations@biotest.de
PR contact
Dirk Neumüller
phone: +49-6103-801-269
email: pr@biotest.de
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany www.biotest.de
Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover,
Munich, Stuttgart
Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.
---------------------------------------------------------------------------
28.09.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations@biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
505879 28.09.2016
Diskutieren Sie über die enthaltenen Werte
Aktuelle Themen
Weitere Artikel des Autors
1 im Artikel enthaltener WertIm Artikel enthaltene Werte